Astrea Bioseparations Acquires Delta Precision Ltd

Gibraltar Industries Acquires Assets of Delta Separations

February 13, 2020

Manufacturing

Gibraltar Industries acquired the assets of California-based Delta Separations for $50 million in an all-cash transaction that closed on February 13, 2020. Delta Separations, a manufacturer of centrifugal ethanol-based extraction systems serving cannabis, hemp and botanical processors, reported 2019 revenue of $46 million and is expected to be accretive to Gibraltar in 2020.

Bruker Corporation Acquires PepSep (nanoLC columns maker)

February 4, 2022

Medical Devices

Bruker Corporation acquired PepSep, a Danish maker of nanoflow liquid chromatography (nanoLC) columns, emitters and components to expand its timsTOF 4D‑Proteomics consumables portfolio. Financial terms were not disclosed; Bruker also announced an OEM agreement with IonOpticks to produce Bruker-branded high-performance pulled-tip columns.

Dragonfly Biosciences Acquires Premium Extraction Services

March 1, 2021

Manufacturing

Dragonfly Biosciences (DragonflyCBD) has acquired full ownership of Premium Extraction Services Limited, a large-scale ethanol CBD extraction facility based in Romania. The acquisition gives Dragonfly in-house extraction capacity capable of producing over 1,000 kg of CBD per month, supporting vertical integration and large-scale supply for its CBD product lines.

CatSci Acquires Reach Separations

June 25, 2024

Healthcare Services

CatSci Ltd, backed by Keensight Capital, has acquired Reach Separations, a specialist chromatography provider headquartered in the United Kingdom. The deal expands CatSci's CMC and separation science capabilities, enabling end-to-end analytical and purification services from discovery through to manufacture for biotech, pharma and related customers.

BioCryst Pharmaceuticals Completes Acquisition of Astria Therapeutics

January 26, 2026

Healthcare Services

BioCryst Pharmaceuticals, Inc. completed its acquisition of Astria Therapeutics, Inc. to strengthen its leadership in hereditary angioedema (HAE) and support long-term growth. The deal adds navenibart, a late-stage long-acting plasma kallikrein inhibitor (Phase 3), and also brings Astria’s early-stage atopic dermatitis program STAR0310 (for strategic alternatives).

ATS Acquires BioDot from Artemis Capital Partners

June 17, 2021

Medical Devices

ATS Automation Tooling Systems Inc. has acquired BioDot, an Irvine, California-based maker of ultra-low volume liquid dispensing and lab automation systems, from Artemis Capital Partners. The acquisition expands ATS's life-sciences and diagnostics automation capabilities and follows BioDot's growth under Artemis since its March 2020 investment.